JP2017093448A5 - - Google Patents

Download PDF

Info

Publication number
JP2017093448A5
JP2017093448A5 JP2016250474A JP2016250474A JP2017093448A5 JP 2017093448 A5 JP2017093448 A5 JP 2017093448A5 JP 2016250474 A JP2016250474 A JP 2016250474A JP 2016250474 A JP2016250474 A JP 2016250474A JP 2017093448 A5 JP2017093448 A5 JP 2017093448A5
Authority
JP
Japan
Prior art keywords
nucleic acid
strand
acid molecule
phosphorothioate
molecule according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016250474A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017093448A (ja
JP6629712B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017093448A publication Critical patent/JP2017093448A/ja
Publication of JP2017093448A5 publication Critical patent/JP2017093448A5/ja
Application granted granted Critical
Publication of JP6629712B2 publication Critical patent/JP6629712B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016250474A 2012-05-22 2016-12-26 細胞内貫通能を持ってｒｎａ干渉を誘導する核酸分子およびその用途 Active JP6629712B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2012-0053950 2012-05-22
KR20120053950 2012-05-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015513901A Division JP6139671B2 (ja) 2012-05-22 2013-05-21 細胞内貫通能を持ってｒｎａ干渉を誘導する核酸分子およびその用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019031549A Division JP6999590B2 (ja) 2012-05-22 2019-02-25 細胞内貫通能を持ってｒｎａ干渉を誘導する核酸分子およびその用途

Publications (3)

Publication Number Publication Date
JP2017093448A JP2017093448A (ja) 2017-06-01
JP2017093448A5 true JP2017093448A5 (cg-RX-API-DMAC7.html) 2017-10-05
JP6629712B2 JP6629712B2 (ja) 2020-01-15

Family

ID=49624096

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015513901A Active JP6139671B2 (ja) 2012-05-22 2013-05-21 細胞内貫通能を持ってｒｎａ干渉を誘導する核酸分子およびその用途
JP2016250474A Active JP6629712B2 (ja) 2012-05-22 2016-12-26 細胞内貫通能を持ってｒｎａ干渉を誘導する核酸分子およびその用途
JP2019031549A Active JP6999590B2 (ja) 2012-05-22 2019-02-25 細胞内貫通能を持ってｒｎａ干渉を誘導する核酸分子およびその用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015513901A Active JP6139671B2 (ja) 2012-05-22 2013-05-21 細胞内貫通能を持ってｒｎａ干渉を誘導する核酸分子およびその用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019031549A Active JP6999590B2 (ja) 2012-05-22 2019-02-25 細胞内貫通能を持ってｒｎａ干渉を誘導する核酸分子およびその用途

Country Status (8)

Country Link
US (3) US10125362B2 (cg-RX-API-DMAC7.html)
EP (2) EP3514236A1 (cg-RX-API-DMAC7.html)
JP (3) JP6139671B2 (cg-RX-API-DMAC7.html)
KR (2) KR101567576B1 (cg-RX-API-DMAC7.html)
CN (2) CN104755620B (cg-RX-API-DMAC7.html)
DK (1) DK2853597T3 (cg-RX-API-DMAC7.html)
ES (1) ES2716818T3 (cg-RX-API-DMAC7.html)
WO (1) WO2013176477A1 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2732929T3 (es) 2010-10-22 2019-11-26 Olix Pharmaceuticals Inc Moléculas de ácido nucleico que inducen interferencia de ARN y usos de las mismas
EP3514236A1 (en) 2012-05-22 2019-07-24 Olix Pharmaceuticals, Inc. Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
KR102279110B1 (ko) * 2014-04-30 2021-07-20 올릭스 주식회사 LasiRNA를 유효성분으로 포함하는 피부 미백용 조성물
EP3766973A1 (en) 2015-04-03 2021-01-20 University Of Massachusetts Oligonucleotide compounds for targeting huntingtin mrna
EP3277811B1 (en) 2015-04-03 2020-12-23 University of Massachusetts Fully stabilized asymmetric sirna
WO2016185934A1 (ja) 2015-05-15 2016-11-24 旭硝子株式会社 化学強化ガラス
CN114306627A (zh) * 2015-08-06 2022-04-12 希望之城 细胞穿透蛋白-抗体缀合物及其使用方法
EP3334499A4 (en) * 2015-08-14 2019-04-17 University of Massachusetts BIOACTIVE CONJUGATES FOR THE RELEASE OF OLIGONUCLEOTIDES
EP3377630A4 (en) 2015-11-16 2020-01-01 Olix Pharmaceuticals, Inc. Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3
US10478503B2 (en) 2016-01-31 2019-11-19 University Of Massachusetts Branched oligonucleotides
JP6944942B2 (ja) 2016-02-02 2021-10-06 オリックス ファーマシューティカルズ，インコーポレーテッド ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療
US10519449B2 (en) 2016-02-02 2019-12-31 Olix Pharmaceuticals, Inc. Treatment of angiogenesis-associated diseases using RNA complexes that target ANGPT2 and PDGFB
KR102339886B1 (ko) * 2016-04-11 2021-12-17 올릭스 주식회사 연결 조직 성장 인자를 표적화하는 rna 복합체를 사용한 특발성 폐 섬유증의 치료 방법
KR101916652B1 (ko) * 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
US11753638B2 (en) 2016-08-12 2023-09-12 University Of Massachusetts Conjugated oligonucleotides
JP7424728B2 (ja) 2017-02-10 2024-01-30 オリック パルマセゥティカルズ インコーポレイテッド Ｒｎａ干渉のための長鎖の二本鎖ｒｎａ
KR102321426B1 (ko) * 2017-02-21 2021-11-05 올릭스 주식회사 남성형 탈모 표적 유전자의 발현을 억제하는 비대칭 siRNA
EP3642341A4 (en) 2017-06-23 2021-06-16 University Of Massachusetts TWO-DAY SELF-RELEASING SIRNA AND RELATED PROCEDURES
WO2019066519A1 (ko) * 2017-09-28 2019-04-04 올릭스 주식회사 결합 조직 성장 인자를 표적으로 하는 rna 복합체를 함유하는 노인성 황반변성의 예방 또는 치료용 약학 조성물
CA3081910A1 (en) 2017-11-13 2019-05-16 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages
KR102553382B1 (ko) * 2017-11-13 2023-07-07 사일런스 테라퓨틱스 게엠베하 세포에서 lpa의 발현을 저해하기 위한 핵산
BR112021002440A2 (pt) 2018-08-10 2021-05-04 University Of Massachusetts oligonucleotídeos modificados visando snps
US11279930B2 (en) 2018-08-23 2022-03-22 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
CA3114396A1 (en) * 2018-09-28 2020-04-02 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
WO2020149702A1 (ko) * 2019-01-18 2020-07-23 올릭스 주식회사 Nrl(neural retina leucine zipper)의 발현을 억제하는 비대칭 sirna
JP2022523467A (ja) 2019-01-18 2022-04-25 ユニバーシティ・オブ・マサチューセッツ 動的な薬物動態を修飾するアンカー
KR102397455B1 (ko) * 2019-05-20 2022-05-13 올릭스 주식회사 PD-1의 발현을 억제하는 비대칭 siRNA
WO2021030213A1 (en) 2019-08-09 2021-02-18 University Of Massachusetts Chemically modified oligonucleotides targeting snps
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
KR102757180B1 (ko) * 2019-11-22 2025-01-21 (주)바이오니아 Ctgf 유전자 특이적 이중가닥 올리고뉴클레오티드 및 이를 포함하는 섬유증 관련 질환 및 호흡기 관련 질환 예방 및 치료용 조성물
KR102259402B1 (ko) * 2020-06-04 2021-06-01 주식회사 아임뉴런바이오사이언스 개선된 안정성을 갖는 핵산 분자 및 이의 용도
WO2022124739A1 (ko) * 2020-12-07 2022-06-16 올릭스 주식회사 ROR-beta의 발현을 억제하는 비대칭 RNAi 유도용 핵산 분자
CN114807127A (zh) * 2021-01-19 2022-07-29 陈璞 用于结缔组织生长因子的小干扰rna及其应用
IL309334A (en) 2021-06-23 2024-02-01 Univ Massachusetts Anti-FLT1 optimized oligonucleotide compounds for the treatment of preeclampsia and other angiogenic disorders
CN119074938B (zh) * 2024-08-29 2025-05-27 上海科若纳生命科技有限公司 一种用于mRNA递送和表达的核酸组合物及其应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837258A (en) 1991-08-30 1998-11-17 University Of South Florida Induction of tissue, bone or cartilage formation using connective tissue growth factor
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
US8202979B2 (en) * 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
CZ308053B6 (cs) 2000-12-01 2019-11-27 Max Planck Gesellschaft Izolovaná molekula dvouřetězcové RNA, způsob její výroby a její použití
US20050282188A1 (en) 2001-05-18 2005-12-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20080188430A1 (en) 2001-05-18 2008-08-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
US20050119202A1 (en) 2001-10-26 2005-06-02 Roland Kreutzer Medicament to treat a fibrotic disease
US20040138163A1 (en) 2002-05-29 2004-07-15 Mcswiggen James RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
EP1857547B2 (en) * 2002-08-05 2020-12-02 Silence Therapeutics GmbH Further novel forms of interfering RNA molecules
US8090542B2 (en) 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
ATE479752T1 (de) 2003-03-07 2010-09-15 Alnylam Pharmaceuticals Inc Therapeutische zusammensetzungen
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
US20040198640A1 (en) * 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
US20050136437A1 (en) 2003-08-25 2005-06-23 Nastech Pharmaceutical Company Inc. Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
WO2005021749A1 (en) * 2003-08-28 2005-03-10 Novartis Ag Interfering rna duplex having blunt-ends and 3’-modifications
US20060134787A1 (en) 2004-12-22 2006-06-22 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
WO2005062937A2 (en) 2003-12-22 2005-07-14 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended sirna
US20060069050A1 (en) 2004-02-17 2006-03-30 University Of Massachusetts Methods and compositions for mediating gene silencing
EP2899278A1 (en) * 2004-03-12 2015-07-29 Alnylam Pharmaceuticals Inc. iRNA agents targeting VEGF
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
EP1793835A4 (en) 2004-09-10 2010-12-01 Somagenics Inc SMALL INTERFERING RNA EFFECTIVELY INHIBITING VIRAL GENE EXPRESSION AND METHODS OF USE THEREOF
US7528118B2 (en) * 2004-09-24 2009-05-05 Alnylam Pharmaceuticals, Inc. RNAi modulation of ApoB and uses thereof
US20060142228A1 (en) 2004-12-23 2006-06-29 Ambion, Inc. Methods and compositions concerning siRNA's as mediators of RNA interference
TWI386225B (zh) * 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
KR20070118703A (ko) * 2005-04-08 2007-12-17 나스텍 파마수티컬 컴퍼니 인코포레이티드 호흡기 바이러스 감염을 치료하는 알엔에이 아이
US8067572B2 (en) 2005-05-25 2011-11-29 The University Of York Hybrid interfering RNA
CN101222936A (zh) 2005-06-24 2008-07-16 英特威国际有限公司 灭活的嵌合疫苗和相关的使用方法
JP2009502138A (ja) * 2005-07-21 2009-01-29 アルナイラム ファーマシューティカルズ インコーポレイテッド ＲｈｏＡ遺伝子のＲＮＡｉ調節及びその使用法
WO2007022506A2 (en) 2005-08-18 2007-02-22 University Of Massachusetts Methods and compositions for treating neurological disease
FR2890859B1 (fr) 2005-09-21 2012-12-21 Oreal Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
US8273700B2 (en) * 2005-09-29 2012-09-25 The Johns Hopkins University Methods and compositions for treatment of cystic fibrosis
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
AU2007212700A1 (en) 2006-01-26 2007-08-16 University Of Massachusetts RNA interference agents for therapeutic use
EP2526968A3 (en) 2006-01-27 2013-05-22 Biogen Idec MA Inc. Nogo receptor antagonists
US20070218495A1 (en) 2006-03-16 2007-09-20 Dharmacon, Inc. Methods, libraries and computer program products for gene silencing with reduced off-target effects
US7700541B2 (en) 2006-04-06 2010-04-20 Nitto Denko Corporation Biodegradable cationic polymers
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
US20100105134A1 (en) 2007-03-02 2010-04-29 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
EP2468864A1 (en) 2007-03-02 2012-06-27 Marina Biotech, Inc. Nucleic acid compounds for inhibiting VEGF family gene expression and uses thereof
EP2530152B1 (en) 2007-05-31 2017-12-27 University of Iowa Research Foundation Reduction of off-target RNA interference toxicity
US20090004668A1 (en) 2007-06-22 2009-01-01 The Board Of Trustees Of The Leland Stanford Junior University Pre-miRNA loop-modulated target regulation
WO2009020344A2 (en) 2007-08-06 2009-02-12 Postech Acad Ind Found Small interfering rnas (sirnas) controlling multiple target genes and method for preparing the same
DK2193140T3 (en) 2007-08-27 2017-01-23 Iglobe Health Inst Llc COMPOSITIONS OF ASYMMETRIC INTERFERRING RNA AND ITS APPLICATIONS
WO2009039173A2 (en) 2007-09-19 2009-03-26 Applied Biosystems Inc. SiRNA SEQUENCE-INDEPENDENT MODIFICATION FORMATS FOR REDUCING OFF-TARGET PHENOTYPIC EFFECTS IN RNAi, AND STABILIZED FORMS THEREOF
EP2205740A2 (en) * 2007-10-02 2010-07-14 Rxi Pharmaceuticals Corp. Tripartite rnai constructs
CA2701845A1 (en) * 2007-10-03 2009-04-09 Quark Pharmaceuticals, Inc. Novel sirna structures
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
KR100949791B1 (ko) 2007-12-18 2010-03-30 이동기 오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도
EP2318528A1 (en) 2008-07-24 2011-05-11 Rxi Pharmaceuticals Corporation Rnai constructs and uses therof
US8946172B2 (en) * 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
US8580562B2 (en) 2008-09-08 2013-11-12 Fukuoka University Inhibitory RNA for modulating the molecular function of ZFAT gene
US8664189B2 (en) 2008-09-22 2014-03-04 Rxi Pharmaceuticals Corporation RNA interference in skin indications
US20100227920A1 (en) 2008-09-29 2010-09-09 The Regents Of The University Of California Aldehyde dehydrogenase inhibitors as novel depigmenting agents
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
EP2398903A1 (en) 2009-02-18 2011-12-28 Silence Therapeutics Aktiengesellschaft Means for inhibiting the expression of ang2
EP2408916A2 (en) * 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP3199165B1 (en) 2009-04-03 2022-06-08 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of kras by asymmetric double-stranded rna
US8472766B2 (en) 2009-08-14 2013-06-25 Massachusetts Institute Of Technology Waveguide coupler having continuous three-dimensional tapering
US9260470B2 (en) * 2009-11-04 2016-02-16 Sungkyunkwan University Foundation For Corporate Collaboration SiRNA structure for minimizing off-target effects caused by antisense strands, and use thereof
KR101207561B1 (ko) 2009-12-15 2012-12-04 주식회사 코리아나화장품 티로시나제의 발현을 저해하는 ｓｉＲＮＡ 올리고뉴클레오타이드 및 이를 함유하는 화장료 조성물
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
CN102918052A (zh) * 2010-03-05 2013-02-06 国立大学法人东京大学 硫代磷酸核糖核苷的制造方法
CN106074591B (zh) * 2010-03-24 2020-01-14 菲奥医药公司 眼部症候中的rna干扰
WO2011140659A1 (en) 2010-05-12 2011-11-17 Centre Hospitalier De L'universite De Montreal Screening assays based on mag and/or abhd6 for selecting insulin secretion promoting agents
WO2012037254A1 (en) * 2010-09-15 2012-03-22 Alnylam Pharmaceuticals, Inc. MODIFIED iRNA AGENTS
ES2732929T3 (es) * 2010-10-22 2019-11-26 Olix Pharmaceuticals Inc Moléculas de ácido nucleico que inducen interferencia de ARN y usos de las mismas
CA2818024C (en) 2010-12-06 2019-09-24 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising positional modifications
PT2670411T (pt) * 2011-02-02 2019-06-18 Excaliard Pharmaceuticals Inc Compostos anti sentido visando um fator de crescimento do tecido conetivo (ctfg) para utilização num método de tratamento de queloides ou cicatrizes hipertróficas
CN103562387A (zh) 2011-03-03 2014-02-05 夸克医药公司 Toll样受体途径的寡核苷酸调剂
CN102719432B (zh) 2011-03-29 2013-10-23 南京大学 特异性抑制肿瘤凋亡抑制基因Bcl2的双链不对称小核酸干扰分子asiRNA及其应用
KR101590586B1 (ko) 2011-05-30 2016-02-01 성균관대학교산학협력단 표적 유전자 발현 억제 및 면역 반응을 동시에 유발하는 이중가닥의 긴 간섭 ｒｎａ
CA3205596A1 (en) 2011-07-18 2013-01-24 University Of Kentucky Research Foundation Protection of cells from alu-rna-induced degeneration and inhibitors for protecting cells
US9707235B1 (en) 2012-01-13 2017-07-18 University Of Kentucky Research Foundation Protection of cells from degeneration and treatment of geographic atrophy
EP3514236A1 (en) 2012-05-22 2019-07-24 Olix Pharmaceuticals, Inc. Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
WO2014043291A1 (en) 2012-09-12 2014-03-20 Quark Pharmaceuticals, Inc. Double-stranded nucleic acid compounds
JP2016525346A (ja) 2013-07-05 2016-08-25 バイオニア コーポレーションＢｉｏｎｅｅｒ Ｃｏｒｐｏｒａｔｉｏｎ 呼吸器疾患関連遺伝子特異的ｓｉＲＮＡ、そのようなｓｉＲＮＡを含む二重らせんオリゴＲＮＡ構造体およびこれを含む呼吸器疾患予防または治療用組成物
WO2015015498A1 (en) 2013-07-31 2015-02-05 Qbi Enterprises Ltd. Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
US9790506B2 (en) 2013-10-02 2017-10-17 The Regents Of The University Of California Diagnostic and screening methods for atopic dermatitis
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
WO2015171641A1 (en) 2014-05-05 2015-11-12 Brigham And Women's Hospital, Inc. Coordinate control of pathogenic signaling by the mir-130/301 family in pulmonary hypertension and fibroproliferative diseases
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
EP3277811B1 (en) 2015-04-03 2020-12-23 University of Massachusetts Fully stabilized asymmetric sirna
KR102772402B1 (ko) 2015-07-27 2025-02-26 올릭스 주식회사 멜라닌 생성을 억제하는 rna 복합체
EP3377630A4 (en) 2015-11-16 2020-01-01 Olix Pharmaceuticals, Inc. Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3
US10519449B2 (en) 2016-02-02 2019-12-31 Olix Pharmaceuticals, Inc. Treatment of angiogenesis-associated diseases using RNA complexes that target ANGPT2 and PDGFB
JP6944942B2 (ja) 2016-02-02 2021-10-06 オリックス ファーマシューティカルズ，インコーポレーテッド ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療
KR102339886B1 (ko) * 2016-04-11 2021-12-17 올릭스 주식회사 연결 조직 성장 인자를 표적화하는 rna 복합체를 사용한 특발성 폐 섬유증의 치료 방법
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
JP7424728B2 (ja) 2017-02-10 2024-01-30 オリック パルマセゥティカルズ インコーポレイテッド Ｒｎａ干渉のための長鎖の二本鎖ｒｎａ

Similar Documents

Publication Publication Date Title
JP2017093448A5 (cg-RX-API-DMAC7.html)
JP2015518721A5 (cg-RX-API-DMAC7.html)
Van Rooij et al. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles
JP2015142558A5 (cg-RX-API-DMAC7.html)
HRP20210612T1 (hr) Postupci i pripravci za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk
JP2014527401A5 (cg-RX-API-DMAC7.html)
ZA202003137B (en) Nucleic acid, composition and conjugate containing same, and preparation method and use
CN110944675A (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
JP2015523853A5 (cg-RX-API-DMAC7.html)
JP2015519057A5 (cg-RX-API-DMAC7.html)
JP2015523855A5 (cg-RX-API-DMAC7.html)
JP2017079776A5 (cg-RX-API-DMAC7.html)
JP2009219504A5 (cg-RX-API-DMAC7.html)
WO2008116860A3 (en) Dsrna compositions and methods for treating hpv infections
JP2015518712A5 (cg-RX-API-DMAC7.html)
JP2015518711A5 (cg-RX-API-DMAC7.html)
JP2018513668A5 (cg-RX-API-DMAC7.html)
EA201100813A1 (ru) Фармацевтическая композиция
JP2013226147A5 (cg-RX-API-DMAC7.html)
WO2012170957A3 (en) Retinoid-liposomes for enhancing modulation of hsp47 expression
WO2011056005A3 (ko) 안티센스 가닥에 의한 오프-타겟 효과를 최소화한 신규한 ｓｉＲＮＡ 구조 및 그 용도
JP2015518710A5 (cg-RX-API-DMAC7.html)
JP2016522674A5 (cg-RX-API-DMAC7.html)
RU2019114706A (ru) Направляемая рнк регуляция транскрипции
JP2010525813A5 (cg-RX-API-DMAC7.html)